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Abstract
As much of the aberrant neural development in Down syndrome (DS) occurs postnatally, an early opportunity exists to
intervene and influence life-long cognitive development. Recent success using neural progenitor cells (NPC) in models of
adult neurodegeneration indicate such therapy may be a viable option in diseases such as DS. Murine NPC (mNPC, C17.2 cell
line) or saline were implanted bilaterally into the dorsal hippocampus of postnatal day 2 (PND 2) Ts65Dn pups to explore
the feasibility of early postnatal treatment in this mouse model of DS. Disomic littermates provided karyotype controls for
trisomic pups. Pups were monitored for developmental milestone achievement, and then underwent adult behavior testing
at 14 weeks of age. We found that implanted mNPC survived into adulthood and migrated beyond the implant site in both
karyotypes. The implantation of mNPC resulted in a significant increase in the density of dentate granule cells. However,
mNPC implantation did not elicit cognitive changes in trisomic mice either neonatally or in adulthood. To the best of our
knowledge, these results constitute the first assessment of mNPC as an early intervention on cognitive ability in a DS model.
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Introduction
The British physician John Langdon Down first described
Down syndrome (DS) almost 150 years ago [1]. Today, DS is the
most common genetic cause of intellectual disability and occurs in
1 in every 766 live births [2]. While other medical conditions
associated with DS are treatable, intellectual disability remains the
most limiting factor. Currently, no treatment can influence the
proper cognitive development in DS and therefore provide life-
long cognitive improvements. The potential of a neonatal
intervention is appealing in DS, because many of the neuroan-
atomical abnormalities associated with DS have yet to develop.
Small alterations in early development could affect the lifelong
trajectory of development in the DS brain.
The triplication of genes in DS manifests in postnatal
developmental delays and adult intellectual disability. In adult-
hood, individuals with DS are compromised in organizing and
consolidating information, and in creating spatial maps [3–5].
These and other cognitive tasks are governed directly and
indirectly by the hippocampus, a structure disproportionately
affected in DS [5–7]. Hippocampal deficiencies include granule
cell hypocellularity and abnormal synaptogenesis [8,9]. These
changes are present in fetal development, but because the
hippocampus is dependent on early experiences to form synapses,
synaptogenesis is not mature until childhood and continues to a
lesser extent throughout life [10]. Proper hippocampal develop-
ment is critical for cognitive development and function, making
the hippocampus a promising structure to evaluate the impact of
early intervention.
Trisomic Ts65Dn mice contain a partial triplication genes that
are the murine homologues of human chromosome 21, the
chromosome triplicated in DS [11]. The overexpression of
analogous genes in the trisomic Ts65Dn mouse causes similar
neuroanatomical and cognitive changes as in individuals with DS,
including hindered neurogenesis, hypocellularity of granule cells in
the dentate gyrus (DG), delays in developmental milestone
achievement, impaired spatial abilities, and deficiencies in
association and recognition memory [12–19]. The similarities
between Ts65Dn mice and human DS make this model ideal to
investigate the potential for early interventions.
Currently, NPC transplantation has proven to be of therapeutic
value in the treatment of several adult neurodegenerative disorders
including Parkinson’s disease and ischemia. In these models, NPC
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glia, and produce growth factors [20–27]. In adult Ts65Dn mice,
we have previously found that NPC implanted into the
hippocampus survived at least for one month and reduced the
age-associated extracellular tau accumulation in the hippocampus
[28,29]. The adult neurodegenerative studies suggest a possible
therapeutic potential for neonatal implantation of NPC as a way to
influence the long-term cognitive outcome of DS. To test the
effects of early neonatal NPC treatment in DS, we implanted
murine NPC (mNPC) or a sham saline control into the
hippocampus of neonatal Ts65Dn mouse pups. We assessed
NPC survival and cellular changes in the dentate gyrus 16 weeks
after implant. Behavior assessments were performed in the
weanling period (Developmental Milestones) and 14–16 weeks
post-implantation.
Results
Implanted mNPC Survival and Differentiation
Implanted mNPC were identified by immunohistochemistry
against green fluorescent protein (GFP). GFP+ cells were found in
the hippocampus and in areas outside the implant area in three
out of six disomic animals and five out of six trisomic animals. Of
the animals with evidence of surviving mNPC, the total numbers
of mNPC suggest that the disomic group had almost three times
more surviving mNPC than the trisomic group (t(33)=6.87,
p,0.0001). By extrapolating from the average number of cells
found per section to the total number of possible sections, an
estimated 5.56% of implanted mNPC survived in disomic brains.
However, the survival rate of implanted mNPC was only 1.89% in
trisomic brains.
In contrast, trisomic brains had better cell survival than disomic
brains when only the GFP+ cells in the hippocampus were
compared (t(18)=7.23, p,0.0001). The hippocampus of trisomic
brains contained 66.29% of all the identified implanted mNPC,
whereas the disomic hippocampus only contained 42.01% of the
identified cells. In the hippocampus, GFP+ cells were discernable
in three of the disomic animals and four trisomic animals (Figures 1
and 2). The distribution of GFP+ mNPC in the hippocampus was
similar between karyotypes, although the GFP+ cells were found in
the pyramidal layers of disomic brains (Figure 1b) more often than
in trisomic brains (Figure 2a,b). Some GFP+ interneurons were
identified based on morphology and co-labeling with reelin in the
stratum radiatum of disomic brains (Figure 1d) and in the oriens of
trisomic brains. Attempts to co-label with neuronal marker,
MAP2, or astrocyte marker, GFAP, found no GFP+ cells that
double labeled for these markers of differentiation. Most GFP+
mNPC had the morphology of undifferentiated progenitor cells
with small, compact soma without neuritic or glial processes.
The comparative differences in the number of implanted cells
identified in the hippocampus, where the mNPC were implanted,
and the rest of the brain indicates a disparity in the degree of
migration from the implant site between the two karyotypes. The
difference is in the number of mNPC that migrated and not the
destination. In both karyotypes, GFP+ mNPC were identified in
the lining of the lateral ventricles, including the neurogenic
subventricular zone (SVZ) and endothelial lining adjacent to the
septum, the corpus callosum, and the entorhinal cortex (Figure 3).
In summary, more trisomic brains were found to have surviving
mNPC than disomic brains. However, of the brains with GFP+
cells, the number of surviving mNPC was greater in the disomic
brain, where implanted mNPC migrated from the hippocampal
site of implantation more often than in the trisomic brains.
Figure 1. GFP+ cells found in the hippocampus of a 16 week
disomic control brain. A. In this disomic brain, robust mNPC survival
was observed with GFP+ cells found in throughout the hippocampus
(black cells, arrows). B. mNPC found in the pyramidal layer of CA3 had
the typical pyramidal neuronal shape (arrows). C. In the DG, mNPC were
found in the subgranule zone, which is the neurogenic layer of the
hippocampus (arrows). D. Double labeling for reelin revealed that some
GFP+ cells found outside of the pyramidal layer of CA3 were reelin+
interneurons (solid arrows). Dashed arrows indicate host reelin+
interneurons. Scale bars in A=500 mm and in B–D=100 mm.
doi:10.1371/journal.pone.0036082.g001
Figure 2. GFP+ cells found in the hippocampus of a 16 week
trisomic brain. A. GFP+ cells (black cells, arrows) were most often
found in CA1 and CA3. Scale bar=500 mm. B. A magnification of the
box in A, shows that GFP+ cells were found in the all three layers of CA3
(arrows).
doi:10.1371/journal.pone.0036082.g002
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While hypocellularity in the DG associated with DS has been
previously reported, [16,19], the current study did not find any
differences in the granule cell density between the karyotypes (F(1,
32)=.003, p.0.05) (Figure 4a). However, the implantation of
mNPC did significantly increase the density of granule cells by
33% compared to no treatment controls (F(2, 32)=5.08, p,0.05).
Treatment with saline did not have the same effect (p.0.05). Both
karyotypes were affected equally by the implantation of mNPC
(F(2, 32)=0.86, p.0.05). The increased density of cells in the
mNPC implanted brains may have resulted from the significant
decrease in the diameter of the granule cells (F(2, 32)=6.91,
p,0.05). Post hoc analysis indicated that the average cell diameter
was similar in untreated brains (7.160.19 mm) and saline
implanted brains (6.860.2 mm). However, cell diameters in
mNPC implanted brains were smaller than those in untreated
brains by 13.8% (average diameter 6.160.19 mm) (Figure 4b).
Again, the differences in density were not specific to one karyotype
(F(2, 32)=0.88, p.0.05). General observations of the DG depicts
better organization in mNPC implanted groups as indicated by
less space between cells and a column-like assembly (Figure 5).
Neuroimmune Response to Implantation
Although the brain is a partially immunologically privileged site,
it was important to ascertain if the host responses to the
implantation procedure or mNPC differed between the karyo-
types. Staining for microglia (Iba1) or astrocytes (GFAP) did not
reveal a highly dense pattern of cells associated with an implant
track in either saline or mNPC implanted animals of either
karyotype (Figures S1 and S2). The lack of glial scarring and the
similarity in resident populations of microglia and astrocytes
between implanted and unimplanted groups indicated no long-
term immunoreactivity. Across all groups, astrocytes maintained
an unactivated morphology and an astroglial response towards the
implanted mNPC was never detected 16 weeks after implantation.
Behavioral Assessment Immediately After Implantation
Survival, weight gain, and developmental milestones (DM) were
assessed in all pups from postnatal day 2 (PND 2) to PND 15.
Survival after the implant procedure and in the 48 hours post-
implant was greater than 98%. Post-implant deaths were in
smaller pups (,1.4 grams). The deceased pups were unable to be
karyotyped because of maternal cannibalism. All surviving pups
continued to have milk bands and robust vocalization during
neonatal assessment in the days immediately following PND 2
implantation.
Surviving pups showed steady and typical weight gain over time
for their karyotypes. Trisomic pups weighed significantly less than
disomic pups at time of treatment (mean=1.8 grams trisomic vs.
2.3 grams disomic pups, p,0.05) and throughout early develop-
ment (F(13, 2158)=5.92, p,0.001). Implantation of mNPC or
saline did not affect weight gain in either karyotype through
weaning, with implanted groups having similar weights as their
respective untreated karyotype controls (F(26, 2158)=0.50,
p.0.05) (Figure S3).
The achievement of motor skill DMs (righting response, cliff
avoidance, and negative geotaxis) occurred between PND 5 and
PND 10, whereas eye and ear opening milestones emerged
between PND 11–13. Occasionally, pups would have a mature
Figure 3. GFP+ cells found in areas outside of the hippocampus. A. Half of trisomic mice had GFP+ cells in the entorhinal cortex (arrows). B.
GFP+ cells were found near the lateral ventricles in the septum (arrows). C. GFP+ mNPC also were found in the CC and again in the underlying septal
areas (arrows). rf, rhinal fissure; lv, lateral ventricles; CC, corpus callosum. Scale Bars in A=100 mm and in B–C=200 mm.
doi:10.1371/journal.pone.0036082.g003
Figure 4. Treatment with mNPC significantly increased the
density of the granule cells and decreased their diameter. A.
There was no difference in the density of granule cells between disomic
and trisomic mice overall. However, treatment with mNPC significantly
increased the density of the granule cells (p,0.05). While this effect is
more clearly observable in the disomic/NPC group (#), the interaction
between treatment and karyotype suggests that mNPC effect was
present in both karyotypes. B. Animals implanted with mNPC had
granule cells with significantly smaller cell soma than untreated or
saline treated animals (p,0.05). Again, this is best observed in the
disomic group (#) although statistically both mNPC groups were
affected. Mean 6 SEM shown.
doi:10.1371/journal.pone.0036082.g004
Neonatal NPC Treatment in a Down Syndrome Model
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e36082motor skill response before treatment occurred on PND 2, and
such pups were not included in the statistical analysis for that
milestone. Thus, the number of litters and total number of pups
contributing to each milestone differed (see Table S1 and
Methods).
Righting Response. The righting response is dependent on
the coordination of muscles and detection of the supine position. A
two-way ANOVA confirmed significant differences between
karyotypes in the time to develop a mature righting response
F(1, 214)=34.123, p,0.0005) (Figure 6a). Disomics achieved the
righting response 27.3 hours earlier than trisomics. Treatment
with saline or mNPC did not significantly alter the righting
response (F(2, 214)=2.73, p.0.05), nor was there an interaction
between the karyotype and treatment (F(2, 214)=0.66, p.0.05).
Cliff Avoidance. Cliff avoidance relies on the detection of a
short drop in front of the pup and the physical ability to turn away
from the cliff. Analyses revealed a significant difference in the time
to develop this ability between the disomic and trisomic pups (F(1,
198)=56.88, p,0.0005) (Figure 6b). All disomic groups,
regardless of treatment, achieved a developed response
approximately 36 hours before any trisomic group. Again,
neither implant type further delayed the development of cliff
avoidance (F(2, 198)=2.49, p.0.05), nor was there a significant
interaction (F(2, 198)=1.02, p.0.05).
Negative Geotaxis. Pups placed on an inclined plane with
their nose pointing down will turn so that their nose points uphill.
Again, trisomic pups were delayed in this DM by as much as
24 hours compared to disomic pups (F(1, 132)=11.05, p,0.005)
(Figure 6c). However, treatment with mNPC preferentially
inhibited the disomic pups (F(2, 132)=5.15, p,0.05). Disomic
mice implanted with mNPC were delayed to a level that was
indistinguishable from the trisomic groups (p.0.05) and
significantly longer than either the untreated or saline disomic
groups (p.0.05). In trisomic mice, no additional delays beyond
the initial karyotype-induced delay were found (p,0.05), with no
significant differences between the implanted and untreated
groups.
Eye and Ear Opening. At birth, eyelids are shut, the ear
pinnae (external ear flap) lay flat against the head, and ear canals
are sealed. Events of neonatal development are eye opening, and
the pinnae rise away from the head and the ear canal opening. In
the present study, both eye and ear opening occurred later in
development than the motor milestones, between 9 and 11 days
after PND 2. A two-way ANOVA revealed that a significant
difference in the time to eye opening existed between the two
karyotypes, although the trisomic delay was only 19.5 hours (F(1,
215)=66.31, p,0.0005). Treatment with either saline or mNPC
produced no significant differences between disomic or trisomic
mice, indicating that implants had no adverse effects on eye
opening (F(2, 215)=1.48, p.0.05), nor was the interaction
significant (F(2, 215)=0.60, p.0.05) (data not shown).
Results from the ear opening milestone indicated the same
overall trisomic delay seen in the eye opening response, with a
delay of 24.4 hours (F(1, 215)=88.69), p,0.005) (Figure 6d).
Unlike the eye opening response, treatment significantly delayed
the time to ear canal opening (F(2, 215)=12.82, p,0.0005).
Treatment with mNPC produced a delay of 11.0 hours in
comparison to untreated pups, with saline implantation producing
an additional 6.7 hour delay (p,0.05). This treatment effect was
consistent across both karyotypes, as indicated by an insignificant
interaction (F(2, 215)=2.23, p.0.05).
Figure 5. Organizational differences in the granule cells of the DG. Untreated disomic brains (A) had a lower density of granule cells, with a
correspondingly larger cell diameter. Similar results were reported for untreated trisomic mice (C). In both groups, the granule cell layer appears less
organized in that there was more space between the cells (arrows in A) and randomness to their location within the layer. In contrast, in the Disomic/
mNPC mice (B) and Trisomic/mNPC mice (D), both of which had smaller cell diameters and a tendency towards a higher cell density, have a more
organized appearance. The granule layers of these groups have tightly aligned cells, which sometimes appear to be in rows and columns (arrow
heads in B). Scale bars in A–D are equal to each other and represent 100 mm.
doi:10.1371/journal.pone.0036082.g005
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Plus Maze. The Plus Maze is dependent on spontaneous
exploration and measures the ability to remember previously
visited locations. A cognitively intact animal will show greater
exploration of arms not recently visited, resulting in increased
novel alternations. Trisomic mice made an average of 5 more arm
total entries than disomic mice (F(1, 73)=4.36, p,0.05), although
this was not affected by either treatment (F(2,73)=0.22, p.0.05),
nor was there an interaction (F(2,73)=0.76, p.0.05). Because of
this difference in total arm entries, data were normalized to the
total number of possible novel alternations based on actual
number of arm entries for each animal. Total arm entries ranged
from an average of 30.2 arm entries in Disomic/mNPC mice to
40.4 in Trisomic/mNPC mice for the single 8 minute trial.
Chance performance, based on 4/5 novel arm entries, has been
previously determined to be 44% [14]. A single sample T-test was
used to determine if individual groups were performing signifi-
cantly above this chance performance. All disomic groups
alternated at a level significantly above chance, indicating
purposeful exploration (p,0.0005 for each disomic group).
Trisomic/No tx mice had a novel alternation rate of 49.6%
which was not significantly above chance (t(8)=1.46, p.0.05).
Trisomic/Saline mice also did not alternate above chance
(t(8)=1.90, p.0.05). However, the Trisomic/mNPC group, with
an alternation rate of 62.1%, did alternate significantly above
chance (t(12)=3.82, p,0.005) indicating that this group, like the
disomic groups, had a purposeful alternation approach (Figure 7).
Although some groups performed above chance, a two-way
ANOVA was used to determine if there were significant
differences in the overall number of novel alterations. In the
percentage of novel alternations, there was a main effect of
karyotype, with trisomic mice in general making fewer novel
alternations than disomic mice (F(1,73)=6.17, p,0.05) (Figure 7).
Treatment with saline or mNPC did not significantly change the
percentage of novel alternations (F(2,73)=0.32, p.0.05), nor was
there an interaction between karyotype and treatment
(F(2,73)=0.53, p.0.05). Thus, while the Trisomic/mNPC group
performed above chance, the total number of novel alternations
was not significantly different from the other trisomic groups.
Morris Water Maze (MWM) - Cued Platform and Swim
Speeds. A cued platform session on Day 1 of the MWM swim
task was used to determine motivation and swimming capabilities
between all groups. Four trials of the visible platform task were
administered on Day 1. Using a repeated measures three-way
ANOVA, it was found that the trisomic groups had longer escape
latencies overall compared to the disomic groups (F(1,62)=9.60,
p,0.005). However, the rate at which latencies shortened over the
four trials was not significantly different (F(3, 186)=0.60, p.0.05),
Figure 6. Trisomic pups were delayed in DMs and did not improve with treatment. A, B. Righting response (A) and the cliff avoidance (B)
were delayed in trisomic pups and this delay was not altered by the implantation of saline or mNPC. C. Trisomic pups were also delayed in negative
geotaxis. While trisomic pups were unaffected by treatment, the implantation of mNPC significantly delayed disomic pups to a degree that was
comparable to the significant delays observed in the trisomic pups. D. Trisomic pups were delayed in time to ear canal opening. Treatment with both
mNPC produced a delay in ear opening compared to untreated pups, while treatment with saline produced a significant additional delay. There was
no interaction effect, indicating that both karyotypes were affected in a similar manner. * A significant main effect of karyotype indicates that overall
trisomic pups were delayed compared to disomics. ‘ Indicates a significant delay due to the main effect of treatment regardless of karyotype (post
hoc p,0.05). ‘n’ is the total number of pups in each group. Average day of achievement 6 SEM shown.
doi:10.1371/journal.pone.0036082.g006
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perform the task (Figure S4a). Treatment with saline or mNPC did
not produce significant effects on motivation (F(2, 62)=0.19,
p.0.05) or a significant interaction (F(6, 186)=0.68, p.0.05).
Analysis of swim speeds indicated that there were no significant
differences in the speed at which animals swam in the MWM as a
result of karyotype (F(1,40)=0.05, p.0.05), treatment (F(2,
40)=0.89, p.0.05), or as an interaction between the two
variables (F(2, 40)=0.20, p.0.05). Thus, differences in latencies
measured during the hidden platform task on Days 2–7 reflect
changes in learning and not in motivation or swimming abilities.
Morris Water Maze - Hidden Platform. On Days 2–7 of
the MWM, mice were trained in the spatial portion of the maze in
which the platform is hidden under one cm of opaque water. A
repeated measures three-way ANOVA revealed significant
karyotype differences across the daily average latency
(F(5,310)=3.64, p,0.05). Disomic mice, regardless of treatment,
significantly decreased their latency between Day 2 and Day 3
(p,0.05), but then slowed to an asymptotic level of performance
on Days 3–7 (p.0.05), suggesting that this group successfully
learned the task after two days of training (Figure 8). By
comparison, the trisomic groups did not reach an asymptotic
level of performance until Day 5, as indicated by no significant
decreases in latency between Days 5–7 (p.0.05) (Figure 8).
Treatment with either saline or mNPC did not affect the ability of
either karyotype of mice to learn the location of the hidden
platform (F(10, 310)=0.99, p.0.05).
In the probe trial, the hidden platform was removed and the
number of times the animal crossed the former platform site was
recorded. Trisomic mice overall had significantly fewer platform
crossings than disomic mice (F(1,61)=4.36, p,0.05). Treatment
had no significant effect on the number of platform crossings (F(2,
61)=0.15, p.0.05) (Figure S4b).
Conditioned Taste Avoidance (CTA). CTA is a classical
conditioning task, in which animals must learn the association
between a novel stimulus (chocolate milk, CS) and an
unconditioned aversive response (nausea). Cognitively intact
animals will reduce their consumption of the CS on second
exposure. Previous work in our laboratory has shown that trisomic
Ts65Dn mice are impaired in their ability to form a CTA, and
that this test can be used as a screen for novel treatments designed
to improve cognition in DS (K.N. Maclean, unpublished data).
Average daily water consumption on training days 2–5 did not
differ between the two karyotypes (F(1, 90)=0.16), p.0.05) or as a
result of treatment (F(2,90)=1.98, p.0.05). All groups consumed
between 1.3 and 1.6 mLs of water a day. The amount of CS
consumed on first exposure (Training Day) was not affected by
either karyotype (F(1,90)=2.37, p.0.05) or treatment
(F(2,90)=0.95, p.0.05), or as a function of the interaction
between karyotype and treatment (F2,90)=0.28, p.0.05), indi-
cating that all groups preferred the CS to water (Figure S5).
Consumption levels for each group exceeded that of normal water
consumption by more than 35%. Individual mice that had a
greater than 10% avoidance of the CS on first exposure compared
to normal water drinking were identified as neophobic (n=12).
These animals were excluded from further CTA analyses
(Neophobic mice by group: Disomic/No tx n=3; Disomic/Saline
n=2; Disomic/mNPC n=0; Trisomic/No tx n=2; Trisomic/
Saline n=1; Trisomic/mNPC n=4).
The difference in CS consumption between first and second
exposure indicated that trisomic mice did not avoid the CS on
second exposure to the same degree as disomic mice
(F(1,90)=8.36, p,0.005). As reported above, the first experience
with the CS induced an increase in CS consumption in both
karyotypes by more than 35%. During the second experience with
the CS, the disomic mice reduced their CS drinking by more than
60% on the second exposure (Figure 9). This decrease was
significantly greater than the change measured in trisomic mice,
which as a group had less than a 40% reduction (p,0.05),
suggesting the association between the CS and nausea was not as
strongly learned in the trisomic mice. Treatment with saline or
mNPC did not affect CS consumption on second exposure
(F(2,90)=1.72, p.0.05), nor was there an interaction of karyotype
and treatment (F(2,90)=0.24, p.0.05).
Novel Object Recognition (NOR). Novel object recognition
relies on memory for familiar objects and the preference to explore
novel objects. A repeated measures three-way ANOVA comparing
total exploration time, irrespective of which object, indicated that
Figure 7. Novel alternations did not differ but mNPC treatment
increased Trisomic performance above chance performance.
Overall, trisomic mice showed significantly fewer novel alternations
compared to disomic mice (* p,0.05). Treatment with either saline or
mNPC did not significantly change the number of novel alternations in
either karyotype compared to their respective controls. However,
trisomic mice treated with mNPC alternated significantly above chance
alone (solid line), while untreated and saline treated trisomic mice did
not. Mean 6 SEM shown. * Significant main effect of karyotype. ‘ Novel
alternations were significantly above chance.
doi:10.1371/journal.pone.0036082.g007
Figure 8. In the MWM, all groups improved hidden platform
task performance at a similar rate. All groups had decreasing
latencies across the 6 days of hidden platform testing, as indicated by
the parallel slopes of the lines; however, the trisomic groups were
consistently slower than the disomic groups. Treatment did not affect
the latency to the hidden platform in either karyotype.
doi:10.1371/journal.pone.0036082.g008
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behavior as a function of karyotype (F(1,26)=0.08, p.0.05),
treatment (F(2,26)=0.12, p.0.05), or their interaction (F(2,
26)=0.318, p.0.05)(Figure S6). Exploration behavior was
highly variable between individual mice, with some mice only
exploring 15 seconds and other spending as much as 90 seconds.
To verify that the ability to remember a familiar object was not
dependent on the amount of time mice initially spent exploring it,
a Pearson’s r moment correlation was used to determine that the
time exploring during Exposure 1 was not significantly correlated
to individual memory data taken during Exposure 2 (Pearson’s
r=0.02, n=32).
Memory for a familiar object, and thus the ability to recognize a
novel objects, was determined using a discrimination index (DI). If
both objects were explored equally, then the DI would
approximate zero. When a novel object is explored more, it is
indicated by a positive DI suggesting a better memory for familiar
objects. All groups had an average DI measure above zero. A two-
way ANOVA indicated that across groups, the DI measures were
not significantly different as a function of karyotype
(F(1,26)=0.77, p.0.05), treatment (F(2,26)=1.13, p.0.05), or
as function of their interaction (F(2,26)=1.63, p.0.05) (Figure 10).
Thus, trisomic mice were not impaired in this task, and explored
the novel objects to a similar degree as the disomic controls.
Further, treatment did not alter the time spent exploring novel
objects.
Discussion
This study was designed to investigate the effects of a neonatal
mNPC intervention on the cognitive and neuroanatomical
changes that occur in DS, compared to sham saline and untreated
controls. The implantation of mNPC may not be a viable early
intervention for DS at this time. Despite evidence of some long-
term survival, there were no reliable improvements in cognitive
function.
Both the trisomic and disomic neural environments allowed for
the survival of implanted mNPC throughout the changes
associated with neonatal development, adolescence, and adult-
hood. While the rate of survival was low, the proportion of animals
with surviving implanted cells was higher than those previously
reported [30]. Further, a greater proportion of trisomic brains had
surviving cells than disomic brains, even though the disomic brains
had greater total numbers surviving and greater migration.
Although the brain is a partially immunologically privileged site,
the limited survival of implanted cells remains a significant
challenge in the field of cell transplantation research. We had
hypothesized that by implanting at PND2, we might overcome the
low post-implantation survival rate of NPC reported in many adult
Figure 9. Trisomic mice continued to drink significantly more CS on second exposure than disomic mice. There was no significant
difference in degree of preference during first exposure between disomic and trisomic animals. During the second exposure disomic mice had a
greater avoidance of the CS than the trisomic animals (* p,0.05). Treatment did not preferentially affect CTA learning and affected both karyotypes
to the same degree. Mean 6 SEM shown.
doi:10.1371/journal.pone.0036082.g009
Figure 10. All groups recognized the novel object. All groups
exhibited a preference for the novel object, as indicated by a DI above
zero. While there is apparent variability, the differences in the DI
between groups did not reach significance (p.0.05). Mean 6 SEM
shown.
doi:10.1371/journal.pone.0036082.g010
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the formation of a glial scar, another limitation to effective
transplantation, but did not increase the number of surviving
implanted cells compared to these previous studies.
Earlier studies suggest that implanted NPC migrate to sites of
damage in the injured brain by following chemokine signals
[33,34]. The presence of implanted mNPC in certain areas of the
brain may indicate a need for support in those areas. In the
current study, we found that the implanted mNPC had migrated
throughout the brain in both karyotypes. However, trisomic brains
contained more mNPC at the site of implantation, the hippocam-
pus, than did disomic brains. This may indicate that the
hippocampus in trisomic mice is especially compromised, but
not enough mNPC survived to affect cognition. Alternatively, the
low migration rate may suggest that implanted mNPC did not or
were unable to migrate readily in the trisomic host environment.
One mechanism we investigated for producing long-term
change in the trisomic brain was the potential for mNPC to
decrease the DG hypocellularity reported in Ts65Dn mice
[16,19,35]. A karyotype specific hypocellularity was not found in
this study. This could result from differences in quantification
methods or, more likely, the postnatal handling during DM
assessment, which can increase the retention of immature and
mature DG neurons [16,19,36,37]. Despite the lack of karyotype
controlled changes, implantation with mNPC, but not saline,
resulted in an increased density of dentate granule cells. We did
not find evidence that implanted mNPC differentiated into
granule cells, as the total number of mNPC found in this area
could not account for the 33% increase in granule density
measured in implanted animals. This would suggest that the effects
of the mNPC are indirect, facilitating an environment that
promotes endogenous DG neurogenesis, a phenomenon that has
been previously reported in the aged hippocampus implanted with
NPC [32]. This ability to increase the density of the DG may have
beneficial effects in older Ts65Dn mice, which also have fewer
neurons in the DG [16].
No significant effects of mNPC implantation on cognition were
found. It is possible that the low number of surviving cells was not
enough to affect cognition. While some individual animals that
received implantations of either saline or mNPC had impressive
performances in some behavior tasks, the effects were not
consistent within karyotypes, treatments, or across tasks. The
limited survival of implanted cells precluded statistically meaning-
ful correlations with behavior data, and the degree to which
survival corresponded with improved performance on behavioral
tasks was inconsistent.
Concluding Remarks
The current study confirmed the cognitive deficits of trisomic
Ts65Dn mice compared to disomic mice in Developmental
Milestones, Plus Maze, MWM, and CTA measures of cognition.
The treatment with mNPC did not enhance the cognitive function
of either trisomic or disomic mice. Low surviving numbers of
mNPC and modest changes in granule cell density may not have
been sufficient to produce changes in behavior. However, while
the implanted mNPC did not affect the cognitive abilities of the
trisomic mice in adulthood, it is possible they will offer some
protection against the secondary cognitive decline of Alzheimer’s
disease that emerges in DS [38,39]. The modest improvement in
granule cell density and novel alternations in the Plus maze could
be suggestive of differences that will be significant with time. These
results contribute to a growing foundation of information on
developmental delays and cognitive impairments in the Ts65Dn
mouse, confirming the fidelity of this model with previous studies
and providing insight into possible alternative treatment innova-
tions in the future.
Methods
Ethics Statement
All animal manipulations and housing were in accordance with
the National Institutes of Health Guidelines for the Care and Use
of Laboratory Animals. Protocols were approved by the
Institutional Animal Care and Use Committee at the University
of Colorado Denver which holds the following permits and
accreditations: American Association for Accreditation of Labo-
ratory Animal Care (AAALAC; file 00235), PHS Animal Welfare
Assurance of Compliance (number A3269-01), USDA License
(#84-R-0059). Neonatal implantation and adult euthanasia were
done following the guidelines for age appropriate anesthesia and
euthanasia. Every effort was made to minimize pain and distress.
Animals and Husbandry
The Ts65Dn mouse is a commonly used model for studying
cognitive impairment in DS [40–43]. Approximately 25% of pups
in a litter express a partial triplication of mouse chromosome 16,
which contains 60% of the genes human chromosome 21 [11,44].
Disomic littermates provided karyotype controls. Monogamous
breeding pairs of trisomic Ts65Dn females (Jackson labs stock
#001924) and C57Bl/6JEixC3H/HeJ F1 generation disomic
males were housed in a temperature/humidity controlled room on
a reverse 12-hour light/dark cycle. The colony was propagated
using the Ts65Dn female offspring from the original pairings and
C57Bl/6JEixC3H/HeJ F1 generation disomic males (offspring of
Jackson labs female C57/Bl/6JEi Jax #JR 0924 and male C3H/
HeJ Jax #JR 000659 pairings). Dams were monitored daily for
new litters and day of birth was defined as PND 0. On PND 2, all
pups in a litter were implanted with mNPC (n=16 litters) or saline
(n=20 litters) as described below. Additional litters (n=16)
remained unimplanted, as controls for the implant procedure.
Pups were weaned, separated by gender into groups of 3–5, and
karyotyped by fluorescent in-situ hybridization (FISH) using blood
smears derived from tail snips as previously described on PND 21
[17]. Only male mice were used in behavior studies at 16 weeks, as
females were used for breeding purposes. Mice with the retinal
degeneration mutation Pde6b(rd1), which results in blindness,
were identified by examination with an indirect ophthalmoscope.
These mice were excluded from all adult behavior studies except
CTA. Food and water were provided ad libitum, except during the
CTA.
Neural Progenitor Cells - C17.2 mNPC line
The C17.2 mNPC line (provided by Dr. Evan Snyder, Sanford-
Burnham Medical Research Institute) is a clonal multipotent
disomic NPC line derived from postnatal male mouse cerebellum,
immortalized with v-myc [30,45] and stably transfected with green
fluorescent protein (GFP). The cell line has been characterized as a
true progenitor cell line, capable of differentiation into both neural
and glial cells, migration to sites of damage, synaptic integration
with host tissue, and secretion of growth factors [20,22,25,46–52].
As C17.2 cells are committed to a CNS lineage, their
tumorogenicity is low [30]. This immortalized cell line possesses
the qualities of undifferentiated NPC, making it suitable for
transplantation studies.
All C17.2 mNPC were maintained as an undifferentiated
monolayer on 10 cm
2 tissue culture treated polystyrene plates.
C17.2 mNPC were grown in highly modified DMEM feeding
medium (Dulbecco’s minimal essential medium - Gibco cat.10-
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glutamine, 100 IU/mL penicillin, and 100 mg streptomycin/mL.
All cell culture chemicals were purchased from Invitrogen Life
Technologies unless otherwise indicated. Half of the media was
changed every 2–3 days and cells were split (1:10) weekly, except
when mNPC were prepared for implantation.
For mNPC implant preparation, 90–95% confluent plates were
split (1:5) 48 hours before being used. C17.2 cells were not pre-
differentiated toward a specific neural fate prior to implant. On
implantation day, mNPC were rinsed three times with sterile
Hanks Balanced Salt Solution (HBSS), dissociated using Trypsin-
EDTA (1.5 mL/plate, 0.05%). Cells were concentrated to 100,000
viable cells/ml in sterile 0.09% saline. Trypan Blue exclusion
determined cell viability was .85% in all implant preparations.
Viability counts of mNPC remaining after implant were similar to
counts obtained prior to implant, with only a 62% maximum
difference found.
Implantation Procedure
All disomic and trisomic littermates received the same implant
treatment two days after birth (PND 2). On PND 2, the dam was
separated into a holding cage, and returned to the home cage once
all pups were treated. The separation period averaged 20 minutes
and was always less than 45 minutes, depending on litter size.
During this time, baseline weights and developmental milestones
were taken for each pup.
Pups were cryoanesthetized until non-responsive to stimuli, then
implanted bilaterally with 100,000 undifferentiated C17.2-GFP
mNPC (1 ml) or with 1 ml sterile 0.09% saline. Freehand injections
in the dorsal hippocampus (+2 mm AP, 61 mm LM, 22.5 mm
DV from lambda) were performed using a Hamilton syringe with a
30-gauge needle. The neuroanatomical point lambda (as opposed to
bregma) was used as a reference point, because the overlying blood
vessels at lambda are visible through the skin on PND 2. All
implants were made through the undisturbed skin and skull to
minimize trauma and risk of infection, since the skull is still pliable.
Litters not receiving an implant were removed from the dam for a
period similar the implanted litters and returned to the home cage
without implantation.
Tissue Preparation and Immunohistochemistry
Adult mice were anesthetized with an intraperitoneal injection
of sodium pentobarbital (60 mg/kg) and were perfused intracar-
dially with 0.9% saline followed by fixation with fresh, ice-cold 4%
paraformaldehyde (PFA) for 10 minutes each. Brains then were
removed and stored in fresh 4% PFA overnight at 4uC, then
cryoprotected in a 30% sucrose until they sank, usually 48–
72 hours later. Brains then were embedded in Optimal Cutting
Temperature medium (Tissue Tek, Fisher 14-373-65), sectioned as
freefloating coronal sections (40 mm), and stored at 220uC.
Immunohistochemistry (IHC) was used to identify the survival
of the mNPC in the host brains using anti-GFP (Abcam 290,
1:50K (5 mg/mL), 72 hour incubation). Double-label was done
using anti-GFP and anti-MAP2 (neurons, Chemicon AB5622,
1:500, (1 mg/mL)), anti-GFAP (astrocytes, Millipore MAB360,
1:500, (1 mg/mL)), and anti-reelin (hippocampal interneurons,
Millipore MAB5364, 1:1000, (1 mg/mL)). Single labeling against
anti-GFAP and anti-Iba1 (Microglia, Wako STK 4406, 1:500,
(50 mg/1 mL)) was used to evaluate the glial response. Negative
controls for each antibody included sections from brains without
mNPC (i.e. saline and untreated), as well as the omission of the
primary antibody in mNPC implanted brain sections.
Briefly, sections were rinsed of cryoprotectant, exposed
sequentially to 0.3% peroxidase block, 5% goat serum protein
block, a biotin/avidin block, and placed in primary antibody.
Sections were incubated overnight at 4uC for all primary
antibodies except anti-GFP which was incubated for 72 hours.
After incubation in primary antibody, sections were rinsed and
incubated in a biotinylated secondary antibody or a fluorescent
secondary antibody if double labeling procedures were used.
Biotinylated antibodies were visualized with a 3,39-diaminobenzi-
dine (DAB)-nickel sulfate reaction. After staining, sections were
mounted onto glass slides and coverslipped with Permount.
Fluorescent sections were mounted immediately after rinsing the
secondary antibody and coverslipped using anti-fade mounting
medium.
A subset of animals that underwent behavior testing were used
for pilot studies to determine immunohistochemical and quanti-
fication parameters; these animals are not included in the results.
GFP+ mNPC survival was determined from brain sections taken
every 480 mm and spanning the rostral-caudal range of the brain.
GFP+ cells were never found outside 20.26 to 3.0 mm relative to
bregma, thus only sections within this range were used for
quantifying mNPC survival. Extrapolations using the number of
GFP+ cells weighted by the number of sections in the rostral-
caudal range were used to estimate the percent total surviving cells
[51,53]. A Student’s t-test was used to identify significant
differences between the karyotypes in the total number of
surviving mNPC and the number of mNPC in the hippocampus.
Cell counts were weighted by the total number of sections stained
for GFP. Double labeling to determine mNPC cell fate was
performed on sections taken every 480 mm. Sections taken every
240 mm for GFAP+ astrocytes and every 480 mm for Iba1+
microglia were analyzed to determine if a glial scar resulted from
the neonatal implantation procedure.
Cresyl Violet Staining and Stereology
Quantification of granule cells of the DG was performed on
every 6th section of tissue, approximately every 240 mm.
Unstained sections were mounted, allowed to air dry, rehydrated
in a decreasing series of alcohols, and placed in cresyl violet
staining solution (0.25%). Three sections containing the dorsal
hippocampus (AP-1.70 to 22.30 mm) were used from each brain.
Nine photomicrographs (206 magnification) were taken of the
granule layer of the DG for quantification in each section. The
diameters of fifteen cells in each blade of the DG were measured in
the most rostral section used to determine average cell diameter.
Unbiased stereological methods, based on a modified fraction-
ator method, were used to quantify the number of neurons per
mm
2 area [54]. For each photomicrograph, a 464 grid was
overlaid and neurons were counted in every other square. Cells
crossing the left and/or bottom border of a square were excluded.
The areas of the neuronal layers also were measured from these
photos using the Digimizer Software. The error coefficient (CE(N))
was calculated as previously described [54] and was found to be
less than 0.10, indicating the number of sections and the total area
counted was sufficient to obtain reliable counts. All hippocampal
analyses were made by a researcher blinded to the karyotype and
treatment. Ten percent of sections were counted by a two
additional researchers, who also were blinded to karyotype and
treatment. The average correlation between raters was r=0.94
and the concordance between raters was found using Kendall’s
coefficient of concordance=0.51, indicating that the counts
obtained by all researchers were similar.
A two-way ANOVA was used to determine density differences
between groups. Significance was established at p#0.05 and when
appropriate Fisher’s least significant difference (LSD) post-hoc
comparisons were used.
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Weight and Developmental Milestone (DM)
Assessment. Prior to implantation on PND 2, baseline
weights and five DMs were assessed: righting response, cliff
avoidance behavior, negative geotaxis response, and eye and ear
opening. DM assessment was performed in the same order every
day and assessed similarly to those previously described methods
[12,55,56]. All pups, regardless of sex, were included in the
neonatal behavioral studies. DMs were measured with the
following scoring system: ‘0’ - no response, ‘1’ - attempted or
partial response, and ‘2’ – a complete, developed response. DM
achievement was monitored until the milestone was performed
successfully for two of three consecutive days. The first day of the
three consecutive days with a score of ‘2’ was recorded as the day
of achievement and used in analyses. Pups that could perform a
task during baseline measures on PND 2 were excluded from
analysis for that particular milestone, as the achievement of the
DM occurred before the implantation procedure on PND 2 and
thus its emergence could not be an effect of treatment. For this
reason, the number of pups included in each milestone varied
(Table S1).
Baseline and subsequent postnatal weights were analyzed using
a repeated measures ANOVA, with the following variables:
karyotype (trisomic vs. disomic), treatment (mNPC vs. saline vs.
untreated), and days (PND 2 – PND 15) as the repeated measure.
A Fisher’s least significant difference (LSD) post hoc test was applied
when significant main effects or interaction effects were found
(p#0.05). Weights data were reported as average number of grams
6 SEM for each day.
DM data were analyzed using a two-way ANOVA in which
data was the average day of achievement of the karyotype group
for the litter rather than individual pups. Analyzing the data by
litter, rather than by individual pups, prevents a confounding
effect of litter size, mothering, and within-litter and between-litter
differences that occur in motor development [57–59]. Each litter
mean was weighted by the number of pups in the litter with the
appropriate karyotype designation. Weighted litter means then
were used in statistical analyses. Differences resulting from
karyotype or treatment were determined using a two-way
ANOVA for each DM, with significant differences at p#0.05
and a Fisher’s LSD post hoc test used when appropriate. DM data
were reported as mean day of achievement 6 SEM.
Behavior Testing Methods: Methods for Adult Behavior
Studies
After weaning, male mice were group housed, but tested
individually for behavior. Mice in the same home cage always
were tested in the same order, which occurred during the initial
dark hours of the light/dark cycle. Mice that were positive for
retinal degeneration were excluded from the Plus Maze, Morris
Water Maze, and Novel Object Recognition tasks; neophobic
mice were excluded from CTA. Thus, the number of animals used
in each study varied (Table S1).
Plus Maze (PM). The Plus Maze assesses a mouse’s memory
for recently visited maze arms based on spontaneous alternation.
Rodents inherently choose to explore more novel environmental
stimuli, resulting in ‘novel alternations’ [60]. Ts65Dn mice have a
significantly lower rate of novel alternation in the PM as compared
to disomic control mice at 4 months of age [14]. This test can also
be used as a measure of anxiety, so to avoid confounding the
cognitive results with measures of anxiety, the maze was not
elevated and the four arms were enclosed with clear plexiglass
walls with a white floor, similar to the procedure outlined in [14].
Each arm measured 3 inches wide, 18 inches in length, and had a
black and white visual cue at the end.
In this one trial task, mice were allowed to explore a plus shaped
maze for eight minutes. All sessions were recorded digitally and
manually analyzed for novel alternations, defined as entering four
novel arms within five arm entries. An entry was recorded when all
four feet of the mouse crossed the threshold of the arm. Chance
performance was defined previously as 44% [14]. Learning in this
task was expressed as percentage of novel alternations normalized
to the number of possible alternations, based in the number of arm
entries. Total number of arm entries and novel alternations were
analyzed using two-way ANOVAs and Fisher’s LSD post-hoc test
when appropriate. Significant deviations from chance perfor-
mance were determined using single sample t-tests for each
karyotype/treatment group.
Morris Water Maze (MWM). The MWM depends on
spatial memory to allow a mouse to find a platform below the
water level in opaque water. The task was divided in three parts.
First, a single session of four trials determined swim speed and task
motivation using a submerged platform cued with a flag (visible
platform) (Day 1). Visible platform latencies were analyzed using a
repeated measures three-way ANOVA. Spatial memory was
measured using a hidden platform task in which the platform is
1 cm below water line without a visual cue above water. Average
latency for each of the six days (Day 2–7) of the hidden platform
task (4 trials/day) again were analyzed using a repeated measures
three-way ANOVA, with daily average latency being the repeated
measure. A final probe trial was completed after the four hidden
platform trials on Day 7. In this trial, the platform was removed
and the mouse was allowed to swim feely for 60 seconds. The
number of platform crossings and swim speeds were analyzed
using a two-way ANOVA and Fisher’s LSD post hoc test.
The MWM was performed in a 34-inch diameter circular pool
filled with water made opaque by the addition of non-toxic white
poster paint. Water temperature was 19uC61uC. Four visual cues
were affixed along the walls of the pool and were associated with
four quadrants. Animals were placed in the water facing a visual
cue, in one of the three quadrants that did not contain the
platform. The original visible platform position (Day 1) was
changed in the hidden platform task (Days 2–7). The platform
remained in the same position for all days of the hidden platform
task. The animal’s starting quadrant was randomly determined
and repeated for each mouse in the session. Trials were separated
by 13 minutes, with mice being placed in a dry cage under a
heating lamp to prevent the potentially confounding effects of
hypothermia [61]. One session of four trials occurred daily, and
time to reach the platform was recorded. If at the end of the
60 seconds the mouse had not found the platform, he was guided
to it. Animals were allowed 30 seconds on the platform to
formulate a cognitive map in reference to the four visual cues. All
sessions were digitally recorded and analyzed both manually
(latency, platform crossings) and using AnyMaze Software (swim
speeds).
Conditioned Taste Avoidance (CTA). CTA is a classical
conditioning task where a novel flavor (the conditioned stimulus,
CS) is paired with a feeling of nausea, produced by an injection of
lithium chloride (the unconditioned stimulus, US). The association
between the CS and the US induces an avoidance of the novel
flavor on subsequent exposures [62]. CTA was administered as a
two-bottle paradigm over 8 days. Mice were trained to first drink
their fill of water during 60 minutes each day, then were given an
intraperitoneal (IP) injection of 0.9% sterile saline (0.0075 ml/g)
and returned to their group-housing cage. The amount of water
consumed from each bottle was recorded. On Day 6 (Training
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exposure to the CS. After the 60-minute drinking period, mice
were given an IP injection of 0.4 M lithium chloride (0.0075 ml/
g). After the injection, mice were monitored for signs of nausea.
The amount of CS consumed from both bottles was recorded. On
Day 8 (Test Day), mice were offered one bottle of chocolate milk
(second exposure) and one bottle of water. The amount consumed
from each was recorded.
To characterize and measure CTA, several statistical analyses
were done. A two-way ANOVA compared average water
consumption (Days 2–5) between groups to verify that all groups
drank same amount of water. To validate that all groups had a
similar preference for the CS and to eliminate individual mice with
a neophobic response, the amount of chocolate milk drank on first
exposure (Day 6) was normalized to the average water
consumption on Days 2–5. Mice with a neophobic response were
excluded from further CTA analyses, as determined by a greater
than 10% decrease in chocolate milk intake on first exposure (Day
6) compared to the average amount of water that was consumed
on Days 2–5. Learning was analyzed with a two-way ANOVA
comparing the percent change in normalized CS consumed
between first exposure and second exposure.
Novel Object Recognition (NOR). Cognitively intact
animals will spend more time exploring a novel object over a
familiar object, however trisomic mice have been reported to be
deficient in novel object recognition [63]. A simple discrimination
test paradigm was administered similar to that as described in [64].
Briefly, mice were allowed to explore two identical objects for
15 minutes during Exposure 1. On Exposure 2, 24 hours later,
animals explored a familiar object from Exposure 1 and a novel
object. All sessions were recorded for subsequent manual analysis.
To verify that all groups spent the same amount of time exploring,
the total exploration time (minutes) was analyzed using a repeated
measures three-way ANOVA, with Exposure 1 and Exposure 2
being the repeated measures. A Pearson’s correlation was used to
determine if learning was a function of the amount of exploration.
Learning was measured based on the total time spent exploring the
novel object on Exposure 2, compared to the total time spent
exploring the familiar object on Exposure 2, resulting in a
normalized discrimination index (DI: Novel Object Exploration/Total
Exploration – Familiar Object Exploration//Total Exploration) [18,64]. A
DI of zero indicated that both objects are explored equally; a
positive DI indicated that the novel object was explored
preferentially. A two-way ANOVA was used to analyze the DI
measures.
Supporting Information
Figure S1 Microglial presence in the hippocampus did
not change with mNPC implantation. Resting Iba1+
microglia were spaced evenly throughout the hippocampus in
untreated disomic (A) and untreated trisomic (C) brains. The same
pattern of distribution was seen in Disomic/mNPC (B) and
Trisomic/mNPC (D). (B) and (D) were double labeled for Iba1
and GFP, resulting in higher background. As expected, no
microglia co-labeled for GFP, indicating that implanted mNPC
were not differentiating into a macrophage lineage. A1 is a
magnification of boxed area in A to illustrate the resting
morphology of the microglia. Scale bars in A–D=500 mm.
(TIF)
Figure S2 Astrocyte presence in the hippocampus of 16
week old brains revealed no gliotic scarring. Disomic/No
tx (A) and Trisomic/No tx (C) mice had ubiquitous and evenly
spaced GFAP+ astrocytes, which did not appear to have an
activated morphology. No brain sections were found that had a
condensation of reactive astrocytes suggestive of a gliotic scar. No
differences in the pattern of GFAP+ staining was observed in
Disomic/mNPC (B) or Trisomic/mNPC (D) mice. Gr, granule cell
layer; rad, stratum radiatum; CC, Corpus callosum. Scale Bars in
A–D=500 mm.
(TIF)
Figure S3 Treatment did not alter weight gain in pups.
Typical for trisomic pups, their weights were lower than their
disomic littermates (p,0.001). The implantation of saline or
mNPC did not alter the weight gain of either group (p.0.05).
Mean weight values of each karyotype/treatment group of pups
are shown. *Significantly different weight at PND 21 between all
trisomic and all disomic groups (main effect of karyotype).
Q indicates day of treatment.
(TIF)
Figure S4 Visible platform training and platform
crossings were similar between all groups in the
MWM. A. Trisomic mice as a group had longer average latencies
to reach the visible platform, however all groups improved their
performances over the four trials, as indicated by the parallel lines.
B. In the probe trial, all groups had a similar number of platform
crossings. No group showed an increased tendency to perseverate
in the platform location. Mean 6 SEM shown.
(TIF)
Figure S5 Both disomic and trisomic mice consumed
similar volumes of CS on Training Day. There was no
significant difference in the amount (mLs) of CS consumed by
either karyotype or treatment group on first exposure (p.0.05).
Data subsequently was normalized to the average drinking
behavior for each animal to account for individual variations.
(TIF)
Figure S6 All groups had similar total exploration times
in the NOR. There was large intragroup variability on both days
of exploration, especially for No treatment and Saline treated
groups of both karyotypes. All groups explored significantly less on
Day 2. Mean 6 SEM shown.
(TIF)
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